Patents by Inventor Nicholas Lachance

Nicholas Lachance has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridine analogs as C5a antagonists
    Patent number: 7429666
    Abstract: The present invention provides novel compounds of Formula I which are antagonists of the C5a receptor. Compounds of the present invention are useful for the treatment of various C5a-mediated diseases and disorders; accordingly the present invention provides a method for the treatment of C5a-mediated diseases using the novel compounds described herein, as well as pharmaceutical compositions containing them.
    Type: Grant
    Filed: February 8, 2005
    Date of Patent: September 30, 2008
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Nicholas Lachance, Patrick Roy, Yves Leblanc
  • Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
    Patent number: 7199154
    Abstract: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: April 3, 2007
    Assignee: Merck Frosst Company
    Inventors: Carl Berthelette, Nicholas Lachance, Lianhai Li, Claudio Sturino, Zhaoyin Wang, Robert N. Young, Claude Dufresne
  • Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
    Publication number: 20050261245
    Abstract: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events.
    Type: Application
    Filed: July 24, 2003
    Publication date: November 24, 2005
    Inventors: Carl Berthelette, Nicholas Lachance, Lianhai Li, Claudio Sturino, Zhaoyin Wang, Robert Young, Claude Dufresne
  • Prostaglandin receptor ligands
    Publication number: 20010031766
    Abstract: Compounds and methods for treating prostaglandin mediated diseases, and certain pharmaceutical compositions thereof are disclosed.
    Type: Application
    Filed: February 12, 2001
    Publication date: October 18, 2001
    Applicant: Merck Frosst Canada & Co.
    Inventors: Michel Belley, Nicholas Lachance, Marc Labelle, Michel Gallant, Nathalie Chauret, Laird A. Trimble
  • Prostaglandin receptor ligands
    Patent number: 6211197
    Abstract: Compounds and methods for treating prostaglandin mediated diseases, and certain pharmaceutical compositions thereof are disclosed. The compounds are represented by formula II: Ar1—W—Ar2—X—Q  II The compounds of the invention are structurally different from NSAIDs and opiates, and are antagonists of the pain and inflammatory effects of E-type prostaglandins.
    Type: Grant
    Filed: October 4, 1999
    Date of Patent: April 3, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Michel Belley, Marc Labelle, Nicholas Lachance, Michel Gallant, Nathalie Chauret, Laird A. Trimble, Chun Li